Dr Timothy Hughes

2022

• Carpanini, S. M. et al. 2022. Terminal complement pathway activation drives synaptic Loss in Alzheimer’s disease models. Acta Neuropathologica Communications 10, article number: 99. (10.1186/s40478-022-01404-w)
• Webberley, T. S. et al. 2022. The impact of probiotic supplementation on cognitive, pathological and metabolic markers in a transgenic mouse model of Alzheimer’s Disease. Frontiers in Neuroscience 16, article number: 843105. (10.3389/fnins.2022.843105)
• Westacott, L. J. et al. 2022. Complement C3 and C3aR mediate different aspects of emotional behaviours; relevance to risk for psychiatric disorder. Brain, Behavior, and Immunity 99, pp. 70-82. (10.1016/j.bbi.2021.09.005)

2021

• Westacott, L. J. et al. 2021. Dissociable effects of complement C3 and C3aR on survival and morphology of adult born hippocampal neurons, pattern separation, and cognitive flexibility in male mice. Brain, Behavior, and Immunity 98, pp. 136-150. (10.1016/j.bbi.2021.08.215)
• Baker, L. et al. 2021. A genome guided evaluation of the Lab4 probiotic consortium. Genomics 113(6), pp. 4028-4038. (10.1016/j.ygeno.2021.08.007)
• Webberley, T. S. et al. 2021. The impact of Lab4 probiotic supplementation in a 90-Day study in wistar rats. Frontiers in Nutrition 8, article number: 778289. (10.3389/fnut.2021.778289)
• Al-Ahmadi, W. et al. 2021. Pro-atherogenic actions of signal transducer and activator of transcription 1 serine 727 phosphorylation in LDL receptor deficient mice via modulation of plaque inflammation. FASEB Journal 35(10), article number: e21892. (10.1096/fj.202100571RR)
• Moss, J. W. E. et al. 2021. Protective effects of a unique combination of nutritionally active ingredients on risk factors and gene expression associated with atherosclerosis in C57BL/6J mice fed a high fat diet. Food and Function 12(8), pp. 3657-3671. (10.1039/D0FO02867C)
• Mullish, B. H. et al. 2021. Probiotics reduce self-reported symptoms of upper respiratory tract infection in overweight and obese adults: should we be considering probiotics during viral pandemics?. Gut Microbes 13(1), pp. 1-9. (10.1080/19490976.2021.1900997)

2020

• Bevan, R. J., Hughes, T. R., Williams, P. A., Good, M. A., Morgan, B. P. and Morgan, J. E. 2020. Retinal ganglion cell degeneration correlates with hippocampal spine loss in experimental Alzheimer's disease. Acta Neuropathologica Communications 8(1), article number: 216. (10.1186/s40478-020-01094-2)
• Michael, D. R. et al. 2020. A randomised controlled study shows supplementation of overweight and obese adults with lactobacilli and bifidobacteria reduces bodyweight and improves well-being. Scientific Reports 10(1), pp. -., article number: 4183. (10.1038/s41598-020-60991-7)

2019

• Michael, D., Davies, T., Loxley, K., Allen, M., Good, M., Hughes, T. and Plummer, S. 2019. In vitro neuroprotective activities of two distinct probiotic consortia. Beneficial Microbes 10(4), pp. 437-447. (10.3920/BM2018.0105)

2018

• Boshra, H., Zelek, W. M., Hughes, T. R., Rodriguez de Cordoba, S. and Morgan, B. P. 2018. Absence of CD59 in guinea pigs: Analysis of the Cavia porcellus genome suggests the evolution of a CD59 pseudogene. Journal of Immunology 200(1), pp. 327-335. (10.4049/jimmunol.1701238)

2017

• Michael, D. R. et al. 2017. The anti-cholesterolaemic effect of a consortium of probiotics: An acute study in C57BL/6J mice. Scientific Reports 7, article number: 2883. (10.1038/s41598-017-02889-5)
• Bergfeld, A. et al. 2017. Direct binding of the pH-regulated protein 1 (Pra1) from Candida albicans inhibits cytokine secretion by mouse CD4+ T cells. Frontiers in Microbiology 8 (10.3389/fmicb.2017.00844)
• Granados-Durán, P. et al. 2017. Microbial neuraminidase induces a moderate and transient myelin vacuolation independent of complement system activation. Frontiers in Neurology 8, article number: 78. (10.3389/fneur.2017.00078)

2016

• Granados-Duran, P. et al. 2016. Complement system activation contributes to the ependymal damage induced by microbial neuraminidase. Journal of Neuroinflammation 13(115) (10.1186/s12974-016-0576-9)
• Towner, L. D., Wheat, R. A., Hughes, T. R. and Morgan, B. P. 2016. Complement membrane attack and tumorigenesis: a systems biology approach. Journal of Biological Chemistry 291(29), pp. 14927-14938. (10.1074/jbc.M115.708446)
• Bloom, A. C. et al. 2016. Deletion of the membrane complement inhibitor CD59a drives age and gender-dependent alterations to bone phenotype in mice. Bone 84, pp. 253-261. (10.1016/j.bone.2015.12.014)
• Triantafilou, M., Hughes, T., Morgan, B. and Triantafilou, K. 2016. Complementing the inflammasome. Immunology 147(2), pp. 152-164. (10.1111/imm.12556)

2015

• McCully, M. L., Collins, P. J., Hughes, T. R., Thomas, C. P., Billen, J., O'Donnell, V. B. and Moser, B. 2015. Skin metabolites define a new paradigm in the localization of skin tropic memory T cells. Journal of Immunology 195(1), pp. 96-104. (10.4049/jimmunol.1402961)
• Ramaglia, V., Jackson, S. J., Hughes, T., Neal, J., Baker, D. and Morgan, B. 2015. Complement activation and expression during chronic relapsing experimental autoimmune encephalomyelitis in the Biozzi ABH mouse. Clinical & Experimental Immunology 180(3), pp. 432-441. (10.1111/cei.12595)
• Davies, T. S., Gallagher, H., Jaafar, F., Moss, J. W., Hughes, T. R. and Ramji, D. P. 2015. Interferon gamma signalling in atherosclerosis: pro-atherogenic actions and therapeutic approaches. Cardiology 131, pp. 292-292.

2014

• Towner, L., Hughes, T. and Morgan, B. P. 2014. Exploring the effects of non-lethal complement membrane attack on CT26 Colon Carcinoma cells using network analysis of differentially expressed genes. Molecular Immunology 61(2), pp. 245-246.
• Davies, T. S., Li, N., McLaren, J., Hughes, T. R. and Ramji, D. P. 2014. Pro- therogenic actions of interferon-gamma on macrophages in atherosclerosis. Cardiology 128(S1), pp. 278-278. (10.1159/000365062)
• Steiner, T. et al. 2014. Protective role for properdin in progression of experimental murine atherosclerosis. PLoS ONE 9(3), article number: e92404. (10.1371/journal.pone.0092404)

2013

• Triantafilou, K., Hughes, T. R., Triantafilou, M. and Morgan, B. P. 2013. The complement membrane attack complex triggers intracellular Ca2+ fluxes leading to NLRP3 inflammasome activation. Journal of Cell Science 126(13), pp. 2903-2913. (10.1242/jcs.124388)
• Laudisi, F. et al. 2013. Cutting edge: The NLRP3 inflammasome links complement-mediated inflammation and IL-1β release. The Journal of Immunology 191(3), pp. 1006-1010. (10.4049/jimmunol.1300489)
• Killick, R., Hughes, T. R., Morgan, B. P. and Lovestone, S. 2013. Corrigendum to “Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH” [Neurosci. Lett. 533 (2013) 96–99] [Corrigendum]. Neuroscience Letters 545, pp. 144-144. (10.1016/j.neulet.2013.05.004)
• Killick, R., Hughes, T. R., Morgan, B. P. and Lovestone, S. 2013. Deletion of Crry, the murine ortholog of the sporadic Alzheimer's disease risk gene CR1, impacts tau phosphorylation and brain CFH. Neuroscience Letters 533, pp. 96-99. (10.1016/j.neulet.2012.11.008)
• Kandasamy, M. et al. 2013. Complement mediated signaling on pulmonary CD103+ dendritic cells is critical for their migratory function in response to influenza infection. PLoS Pathogens 9(1), article number: e1003115. (10.1371/journal.ppat.1003115)

2012

• Ramaglia, V. et al. 2012. C3-dependent mechanism of microglial priming relevant to multiple sclerosis. Proceedings of the National Academy of Sciences 109(3), pp. 965-970. (10.1073/pnas.1111924109)

2011

• Lewis, R. D., Perry, M. J., Guschina, I., Jackson, C. L., Morgan, B. P. and Hughes, T. R. 2011. CD55 deficiency protects against atherosclerosis in ApoE-deficient mice via C3a modulation of lipid metabolism. American Journal of Pathology 179(4), pp. 1601-1607. (10.1016/j.ajpath.2011.06.015)
• Lueck, K. et al. 2011. Sub-lytic C5b-9 induces functional changes in retinal pigment epithelial cells consistent with age-related macular degeneration. Eye 25(8), pp. 1074-1082. (10.1038/eye.2011.109)

2010

• Lewis, R. D., Jackson, C. L., Morgan, B. P. and Hughes, T. R. 2010. The membrane attack complex of complement drives the progression of atherosclerosis in apolipoprotein E knockout mice. Molecular Immunology 47(5), pp. 1098-1105. (10.1016/j.molimm.2009.10.035)
• Gray, L. C., Hughes, T. R. and Van Den Berg, C. W. 2010. Binding of human antigen R (HuR) to an AU-rich element (ARE) in the 3' untranslated region (3' UTR) reduces the expression of decay accelerating factor (DAF). Molecular Immunology 47(16), pp. 2545-2551. (10.1016/j.molimm.2010.07.002)
• Copland, D. A. et al. 2010. Systemic and local anti-C5 therapy reduces the disease severity in experimental autoimmune uveoretinitis. Clinical and Experimental Immunology 159(3), pp. 303-314. (10.1111/j.1365-2249.2009.04070.x)

2009

• Hughes, T. R., Ross, K. S., Cowan, G. J. M., Baalasubramanian, S., Harris, C. L., Mitchell, T. J. and Morgan, B. P. 2009. Identification of the high affinity binding site in the Streptococcus intermedius toxin intermedilysin for its membrane receptor, the human complement regulator CD59. Molecular Immunology 46(7), pp. 1561-1567. (10.1016/j.molimm.2009.01.003)
• Ruseva, M. M. et al. 2009. Crry deficiency in complement sufficient mice: C3 consumption occurs without associated renal injury. Molecular Immunology 46(5), pp. 803-811. (10.1016/j.molimm.2008.09.003)

2008

• Donev, R. M., Gray, L. C., Baalasubramanian, S., Hughes, T. R., Van Den Berg, C. W. and Morgan, B. P. 2008. Modulation of CD59 expression by restrictive silencer factor-derived peptides in cancer immunotherapy for neuroblastoma [RETRACTED]. Cancer Research 68(14), pp. 5979-5987. (10.1158/0008-5472.CAN-07-6828)

2007

• Sivasankar, B. et al. 2007. CD59a deficient mice display reduced B cell activity and antibody production in response to T-dependent antigens. Molecular Immunology 44(11), pp. 2978-2987. (10.1016/j.molimm.2006.12.025)

2006

• Donev, R. M., Cole, D. S., Sivanaskar, B., Hughes, T. R. and Morgan, B. P. 2006. p53 regulates cellular resistance to complement lysis through enhanced expression of CD59 [RETRACTED]. Cancer Research 66(4), pp. 2451-8. (10.1158/0008-5472.CAN-05-3191)
• Irvine, S. A., Martin, J., Hughes, T. R. and Ramji, D. P. 2006. Lipoprotein lipase is expressed by glomerular mesangial cells. The International Journal of Biochemistry & Cell Biology 38(1), pp. 12-16. (10.1016/j.biocel.2005.07.008)

2003

• Mead, J. R., Hughes, T. R., Irvine, S. A., Singh, N. N. and Ramji, D. P. 2003. Interferon-γ stimulates the expression of the inducible cAMP early repressor in macrophages through the activation of casein kinase 2: A Potentially novel pathway for interferon-γ-mediated inhibition of gene transcription. Journal of Biological Chemistry, pp. 17741-17751. (10.1074/jbc.M301602200)

2002

• Hughes, T. R., Tengku-Muhammad, T. S., Irvine, S. A. and Ramji, D. P. 2002. A novel role of Sp1 and Sp3 in the interferon- -mediated suppression of macrophage lipoprotein lipase gene transcription. Journal of Biological Chemistry 277(13), pp. 11097-11106. (10.1074/jbc.M106774200)

2001

• Kockar, F. T., Foka, P., Hughes, T. R., Kousteni, S. and Ramji, D. P. 2001. Analysis of the Xenopus laevis CCAAT-enhancer binding protein α gene promoter demonstrates species-specific differences in the mechanisms for both auto-activation and regulation by Sp1. Nucleic Acids Research 29(2), pp. 362-372. (10.1093/nar/29.2.362)

2000

• Granger, R. L., Hughes, T. R. and Ramji, D. P. 2000. Gene, stimulus and cell-type specific regulation of activator protein-1 in mesangial cells by lipopolysaccharide and cytokines. Biochimica et Biophysica Acta (BBA) - Gene Structure and Expression 1492(1), pp. 100-107. (10.1016/S0167-4781(00)00089-0)
• Granger, R. L., Hughes, T. R. and Ramji, D. P. 2000. Stimulus- and cell-type-specific regulation of CCAAT-enhancer binding protein isoforms in glomerular mesangial cells by lipopolysaccharide and cytokines. Biochimica et Biophysica Acta - Molecular Basis of Disease 1501(2-3), pp. 171-179. (10.1016/S0925-4439(00)00016-8)